MT-103 Micromet/MedImmune.
dc.contributor.author | Cheadle, Eleanor J | |
dc.date.accessioned | 2009-07-07T09:48:05Z | |
dc.date.available | 2009-07-07T09:48:05Z | |
dc.date.issued | 2006-02 | |
dc.identifier.citation | MT-103 Micromet/MedImmune. 2006, 8 (1):62-8 Curr. Opin. Mol. Ther. | en |
dc.identifier.issn | 1464-8431 | |
dc.identifier.pmid | 16506527 | |
dc.identifier.uri | http://hdl.handle.net/10541/72697 | |
dc.description.abstract | Micromet AG and Medlmmune Inc are developing MT-103, a single-chain bispecific recombinant antibody from Micromet's BiTE (bispecific T-cell engager) product platform that binds both the CD19 antigen and the T-cell receptor (CD3), for the potential treatment of B-cell lymphoma. The company is also investigating the compound for the potential treatment of chronic lymphocytic leukemia and acute lymphoblastic leukemia. | |
dc.language.iso | en | en |
dc.subject.mesh | Animals | |
dc.subject.mesh | Antibodies, Bispecific | |
dc.subject.mesh | Clinical Trials, Phase I as Topic | |
dc.subject.mesh | Drug Industry | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Lymphoma, B-Cell | |
dc.subject.mesh | Structure-Activity Relationship | |
dc.title | MT-103 Micromet/MedImmune. | en |
dc.type | Article | en |
dc.contributor.department | Paterson Institute for Cancer Research, Department of Medical Oncology, Wilmslow Road, Manchester M204BX, UK. Echeadle@picr.man.ac.uk | en |
dc.identifier.journal | Current Opinion in Molecular Therapeutics | en |
html.description.abstract | Micromet AG and Medlmmune Inc are developing MT-103, a single-chain bispecific recombinant antibody from Micromet's BiTE (bispecific T-cell engager) product platform that binds both the CD19 antigen and the T-cell receptor (CD3), for the potential treatment of B-cell lymphoma. The company is also investigating the compound for the potential treatment of chronic lymphocytic leukemia and acute lymphoblastic leukemia. |